Anti-PAI-1 Monoclonal Antibody Inhibits the Metastasis and Growth of Esophageal Squamous Cell Carcinoma
暂无分享,去创建一个
C. Shou | L. Qu | Chuanke Zhao | L. Meng | Cai-yun Liu | Lixin Wang | Yu-yu Zheng
[1] Furong Huang,et al. Dysregulated ceramides metabolism by fatty acid 2-hydroxylase exposes a metabolic vulnerability to target cancer metastasis , 2022, Signal Transduction and Targeted Therapy.
[2] A. Laurenzana,et al. A Possible Role for PAI-1 Blockade in Melanoma Immunotherapy. , 2021, The Journal of investigative dermatology.
[3] G. Wang,et al. The molecular mechanism of LRP1 in physiological vascular homeostasis and signal transduction pathways. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[4] W. Weichert,et al. uPA‐PAI‐1 heteromerization promotes breast cancer progression by attracting tumorigenic neutrophils , 2021, EMBO molecular medicine.
[5] Quanren Wang,et al. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma , 2021, The oncologist.
[6] D. Waisman,et al. Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy , 2021, Cancers.
[7] A. Cervantes,et al. Checkpoint inhibitors for gastroesophageal cancers: Dissecting heterogeneity to better understand their role in first line and adjuvant therapy. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[9] T. Miyata,et al. Structural Insight into the Two-Step Mechanism of PAI-1 Inhibition by Small Molecule TM5484 , 2021, International journal of molecular sciences.
[10] S. Lavrentiadou,et al. Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells , 2021, Breast Cancer Research and Treatment.
[11] Y. Kakeji,et al. PAI-1 derived from cancer-associated fibroblasts in esophageal squamous cell carcinoma promotes the invasion of cancer cells and the migration of macrophages , 2020, Laboratory Investigation.
[12] Jian-ping Xu,et al. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma , 2020, Cancer communications.
[13] T. Huang,et al. PAI-1-Dependent Inactivation of SMAD4-Modulated Junction and Adhesion Complex in Obese Endometrial Cancer , 2020, Cell reports.
[14] Sung-Bae Kim,et al. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Qing‐Yu He,et al. Advances in targeted therapy for esophageal cancer , 2020, Signal Transduction and Targeted Therapy.
[16] M. Yoshino,et al. AS3288802, a highly selective antibody to active plasminogen activator inhibitor-1 (PAI-1), exhibits long efficacy duration in cynomolgus monkeys. , 2020, Biologicals : journal of the International Association of Biological Standardization.
[17] N. Kim,et al. Association between Five Common Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms and Colorectal Cancer Susceptibility , 2020, International journal of molecular sciences.
[18] Mingdong Huang,et al. Plasminogen activator inhibitor (PAI) trap3, an exocellular peptide inhibitor of PAI-1, attenuates the rearrangement of F-actin and migration of cancer cells. , 2020, Experimental cell research.
[19] Min Zhang,et al. PAI-1 overexpression promotes invasion and migration of esophageal squamous carcinoma cells. , 2020, Yi chuan = Hereditas.
[20] A. Fatehi Hassanabad,et al. Esophageal carcinoma: Towards targeted therapies , 2019, Cellular Oncology.
[21] Y. DeClerck,et al. The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding , 2019, Cancer and Metastasis Reviews.
[22] H. Kwaan,et al. Fibrin and Fibrinolysis in Cancer , 2019, Seminars in Thrombosis and Hemostasis.
[23] B. Heissig,et al. The fibrinolytic factor tPA drives LRP1‐mediated melanoma growth and metastasis , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[24] Sung-Bae Kim,et al. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study , 2019, JAMA oncology.
[25] S. Yuan,et al. Plasminogen activator inhibitor-1 in cancer research. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[26] N. Sun,et al. Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance , 2018, Cell Death & Disease.
[27] Kazuhiro Yoshida,et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial , 2018, The Lancet.
[28] Yue Fan,et al. Oxymatrine inhibits the migration of human colorectal carcinoma RKO cells via inhibition of PAI-1 and the TGF-β1/Smad signaling pathway , 2016, Oncology reports.
[29] A. Pathak,et al. Intracellular Expression of PAI-1 Specific Aptamers Alters Breast Cancer Cell Migration, Invasion and Angiogenesis , 2016, PloS one.
[30] L. Shen,et al. Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial , 2016, Cancer science.
[31] P. Gettins,et al. The High Affinity Binding Site on Plasminogen Activator Inhibitor-1 (PAI-1) for the Low Density Lipoprotein Receptor-related Protein (LRP1) Is Composed of Four Basic Residues* , 2015, The Journal of Biological Chemistry.
[32] Y. DeClerck,et al. Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing. , 2015, Cancer research.
[33] Wei Li,et al. HIF-1α pathway: role, regulation and intervention for cancer therapy , 2015, Acta pharmaceutica Sinica. B.
[34] M. Baltas,et al. Small molecules inhibitors of plasminogen activator inhibitor-1 - an overview. , 2015, European journal of medicinal chemistry.
[35] Yan Zhang,et al. Expression of Bmi-1 and PAI-1 in esophageal squamous cell carcinoma. , 2014, World journal of gastroenterology.
[36] J. Whisstock,et al. Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1 , 2013, Proceedings of the National Academy of Sciences.
[37] H. Emonard,et al. LRP-1: A Checkpoint for the Extracellular Matrix Proteolysis , 2013, BioMed research international.
[38] A. Mazar,et al. The Apparent uPA/PAI-1 Paradox in Cancer: More than Meets the Eye , 2013, Seminars in Thrombosis & Hemostasis.
[39] A. Gils,et al. The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. , 2012, Thrombosis research.
[40] B. Sullenger,et al. Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation. , 2011, Nucleic acid therapeutics.
[41] Heesang Song,et al. Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9. , 2009, Cancer research.
[42] K. Cortese,et al. Clathrin and LRP-1-Independent Constitutive Endocytosis and Recycling of uPAR , 2008, PloS one.
[43] P. Andreasen. PAI-1 - a potential therapeutic target in cancer. , 2007, Current drug targets.
[44] K. Fan,et al. Mechanism of Inactivation of Plasminogen Activator Inhibitor-1 by a Small Molecule Inhibitor* , 2007, Journal of Biological Chemistry.
[45] I. Mikhailenko,et al. Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability , 2005, Journal of thrombosis and haemostasis : JTH.
[46] A. Gils,et al. Plasminogen activator inhibitor-1. , 2004, Current medicinal chemistry.
[47] M. Duffy,et al. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. , 2004, Clinical biochemistry.
[48] N. Brünner,et al. XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro , 2004, Anti-cancer drugs.
[49] P. Quax,et al. Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro , 2004, Clinical & Experimental Metastasis.
[50] P. Carmeliet,et al. Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. , 2003, Cancer research.
[51] A. Gils,et al. The Distal Hinge of the Reactive Site Loop and Its Proximity , 2001, The Journal of Biological Chemistry.
[52] P. Declerck,et al. Identification of a Functional Epitope in Plasminogen Activator Inhibitor-1, not Localized in the Reactive Center Loop , 1998, Thrombosis and Haemostasis.
[53] H. Höfler,et al. Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.
[54] P. Declerck,et al. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. , 1997, Biochimica et biophysica acta.
[55] K. Miwa,et al. An assay system for the modulators of plasminogen activation on the cell surface. , 1991, Thrombosis research.
[56] T. Wun,et al. Plasminogen activation: biochemistry, physiology, and therapeutics. , 1988, Critical reviews in biotechnology.
[57] K. Danø,et al. Monoclonal Antibodies to Human 54,000 Molecular Weight Plasminogen Activator Inhibitor from Fibrosarcoma Cells - Inhibitor Neutralization and One-Step Affinity Purification , 1986, Thrombosis and Haemostasis.